|Question||Study groups||Outcomes at 1–7 days (5 trials)||Weighted EER||Weighted CER||RBR (95% CI)||NNH|
|Conclusion: in patients with acute upper respiratory infection, antibiotics are no more beneficial in terms of general improvement than placebo and are associated with a non-significant increase in adverse effects.|
|*EER = experimental event rate, CER = control event rate, RBR = relative benefit reduction, RRI = relative risk increase, NS = not statistically significant.; RBR, RRI, NNH, and CI calculated from data in article.|
|In patients with acute respiratory tract infections, what is the efficacy and safety of antibiotics (compared with placebo) in curing infection and improving nasopharyngeal symptoms?||Experimental: antibiotics (tetracycline, penicillin, ampicillin, amoxicillin, erythromycin, and cotrimoxizole) Control: placebo||General improvement||51.2%||52.5%||2% (−5 to 10)||NS|
|Adverse effects||9.7%||3.6%||82% (−25 to 340)||NS|
- EBN notebook
Of studies, summaries, synopses, and systems: the “4S” evolution of services for finding current best evidence
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>
EBN Online Journal Club
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.